2018
Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study
Pashankar F, Frazier AL, Krailo M, Xia C, Pappo AS, Malogolowkin M, Olson TA, Rodriguez‐Galindo C. Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study. Pediatric Blood & Cancer 2018, 65: e27111. PMID: 29697191, PMCID: PMC6019185, DOI: 10.1002/pbc.27111.Peer-Reviewed Original ResearchConceptsMalignant germ cell tumorsPediatric malignant germ cell tumorsGerm cell tumorsOncology GroupCell tumorsMarker declineRefractory germ cell tumorsHigh-dose chemotherapyPhase II trialChildren's Oncology GroupGroup of patientsLong-term toxicityRECIST responseSalvage therapyStable diseaseTIP regimenII trialRECIST criteriaElevated markersPartial responseProgressive diseaseStandard therapyAdditional administrationTumor markersPatients
2016
Paediatric extracranial germ-cell tumours
Shaikh F, Murray MJ, Amatruda JF, Coleman N, Nicholson JC, Hale JP, Pashankar F, Stoneham SJ, Poynter JN, Olson TA, Billmire DF, Stark D, Rodriguez-Galindo C, Frazier AL. Paediatric extracranial germ-cell tumours. The Lancet Oncology 2016, 17: e149-e162. PMID: 27300675, DOI: 10.1016/s1470-2045(15)00545-8.Peer-Reviewed Original ResearchConceptsGerm cell tumorsPediatric extracranial germ cell tumorExtracranial germ cell tumorsPediatric germ cell tumorsSignificant long-term toxicityPoor-risk patientsLow-risk patientsPlatinum-resistant diseaseGroup of patientsHigh tumor markersEvidence-based careRisk stratification systemLong-term toxicityCooperative Research GroupExtragonadal tumorsRisk stratificationFuture trialsClinical behaviorPatient outcomesClinical dataAdult diseaseWide age rangeTumor markersTreatment approachesPatients